

www.covid19-druginteractions.org

Interaction Report

Report ID:

Date Produced: 29 August 2024

Treatment	Co-medications
Nirmatrelvir/ritonavir (5 days)	Valsartan

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above. Drug-drug interactions between Covid drugs are NOT assessed in this report.

Interactions with a "green" classification (i.e. no clinically significant interaction) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.covid19-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Nirmatrelvir/ritonavir (5 days) + Valsartan

Coadministration has not been studied. Valsartan is a substrate of the hepatic uptake transporters OATP1B1 and MRP2. Valsartan concentrations may increase due to inhibition of OATP1B1 by ritonavir and also inhibition of MRP2 by ritonavir. Patients should be advised to monitor for signs or symptoms of hypotension. Given the short duration of nirmatrelvir/ritonavir, no dose adjustment is recommended, but consider stopping valsartan for the remainder of the duration of nirmatrelvir/ritonavir treatment if symptomatic hypotension occurs.